Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
04 08 2022
04 08 2022
Historique:
received:
09
11
2021
accepted:
14
04
2022
pubmed:
30
4
2022
medline:
9
8
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are based on a range of novel platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being one of them. Recently, a novel complication of SARS-CoV-2-targeted adenovirus vaccines has emerged: immune thrombocytopenia, either isolated, or accompanied by thrombosis (then termed VITT). This complication is characterized by low platelet counts, and in the case of VITT, also by platelet-activating platelet factor 4 antibodies reminiscent of heparin-induced thrombocytopenia, leading to a prothrombotic state with clot formation at unusual anatomic sites. Here, we detected antiplatelet antibodies targeting platelet glycoprotein receptors in 30% of patients with proven VITT (n = 27) and 42% of patients with isolated thrombocytopenia after ChAdOx1 nCov-19 vaccination (n = 26), indicating broad antiplatelet autoimmunity in these clinical entities. We use in vitro and in vivo models to characterize possible mechanisms of these platelet-targeted autoimmune responses leading to thrombocytopenia. We show that IV but not intramuscular injection of ChAdOx1 nCov-19 triggers platelet-adenovirus aggregate formation and platelet activation in mice. After IV injection, these aggregates are phagocytosed by macrophages in the spleen, and platelet remnants are found in the marginal zone and follicles. This is followed by a pronounced B-cell response with the emergence of circulating antibodies binding to platelets. Our work contributes to the understanding of platelet-associated complications after ChAdOx1 nCov-19 administration and highlights accidental IV injection as a potential mechanism of platelet-targeted autoimmunity. Hence, preventing IV injection when administering adenovirus-based vaccines could be a potential measure against platelet-associated pathologies after vaccination.
Identifiants
pubmed: 35486845
pii: S0006-4971(22)00609-7
doi: 10.1182/blood.2021014712
pmc: PMC9060731
doi:
Substances chimiques
COVID-19 Vaccines
0
Platelet Factor 4
37270-94-3
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
478-490Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 by The American Society of Hematology.
Références
J Virol. 2007 May;81(9):4866-71
pubmed: 17301138
Blood. 2021 Dec 2;138(22):2256-2268
pubmed: 34587242
Nat Immunol. 2011 Oct 30;12(12):1194-201
pubmed: 22037602
N Engl J Med. 2021 Jul 22;385(4):376-378
pubmed: 34010527
J Thromb Haemost. 2009 Feb;7(2):322-9
pubmed: 18826388
Nat Commun. 2015 Jul 17;6:7737
pubmed: 26185093
Exp Hematol. 2013 Sep;41(9):789-98
pubmed: 23727585
N Engl J Med. 2021 Nov 25;385(22):2103-2105
pubmed: 34525282
Blood. 2022 Mar 10;139(10):1564-1574
pubmed: 34587251
Blood. 1987 Dec;70(6):1722-6
pubmed: 2445398
MMWR Recomm Rep. 2006 Dec 1;55(RR-15):1-48
pubmed: 17136024
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12883-8
pubmed: 14569006
J Leukoc Biol. 2020 Oct;108(4):1157-1182
pubmed: 32779243
Haematologica. 2020 Feb 27;106(1):250-254
pubmed: 32107327
Blood. 2021 Jul 29;138(4):350-353
pubmed: 34323939
J Autoimmun. 2021 Jul;121:102662
pubmed: 34051613
FEBS Lett. 2019 Dec;593(24):3461-3483
pubmed: 31769012
Cell Host Microbe. 2016 Jul 13;20(1):36-48
pubmed: 27345696
N Engl J Med. 2021 Oct 28;385(18):1680-1689
pubmed: 34379914
Blood. 2007 Apr 1;109(7):2832-9
pubmed: 17148587
Blood. 2021 Jul 1;137(26):3656-3659
pubmed: 33945605
N Engl J Med. 2021 May 20;384(20):1964-1965
pubmed: 33852795
N Engl J Med. 2021 Sep 30;385(14):1334-1336
pubmed: 34432977
BMJ. 2021 Aug 26;374:n1931
pubmed: 34446426
Cell. 2000 Sep 1;102(5):553-63
pubmed: 11007474
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
N Engl J Med. 2021 Jun 10;384(23):2254-2256
pubmed: 33861524
Nat Med. 2021 Jul;27(7):1290-1297
pubmed: 34108714
J Thromb Haemost. 2021 Jun;19(6):1585-1588
pubmed: 34018298
JAMA. 2021 Jun 22;325(24):2448-2456
pubmed: 33929487
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
BMJ. 2021 May 5;373:n1114
pubmed: 33952445
Blood. 2001 Oct 15;98(8):2442-7
pubmed: 11588041
Lancet Reg Health Eur. 2022 Jan;12:100270
pubmed: 34901912
Transfus Med. 1992 Sep;2(3):181-8
pubmed: 1308828
Adv Drug Deliv Rev. 2020;158:91-115
pubmed: 32598970
Transfus Med Rev. 2020 Oct;34(4):209-220
pubmed: 33051111
Haematologica. 2021 Dec 01;106(12):3034-3045
pubmed: 34407607
Eur J Haematol. 2021 Aug;107(2):173-180
pubmed: 33987882
Nature. 2021 Aug;596(7873):565-569
pubmed: 34233346
N Engl J Med. 1975 Jan 30;292(5):236-41
pubmed: 1089191
Blood. 2000 Oct 1;96(7):2520-7
pubmed: 11001906
Nat Commun. 2020 Nov 13;11(1):5778
pubmed: 33188196
Blood. 1978 May;51(5):771-9
pubmed: 565227
Blood. 2021 Jul 29;138(4):299-303
pubmed: 33988688
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
Haematologica. 2022 May 01;107(5):1193-1196
pubmed: 34435486
Haematologica. 2015 May;100(5):623-32
pubmed: 25682608
Eur J Haematol. 2006 May;76(5):420-6
pubmed: 16466367
Thromb Res. 2021 Jul;203:163-171
pubmed: 34029848
Nat Rev Immunol. 2021 Dec;21(12):753-755
pubmed: 34663971
J Immunol. 1998 May 15;160(10):4776-87
pubmed: 9590224